信必可都保治疗慢性阻塞性肺疾病疗效观察被引量：5

下载PDF

导出

摘要目的:评价吸入信必可都保治疗重度慢性阻塞性肺疾病(COPD)稳定期的临床疗效和安全性。方法:将69例年龄45～75岁重度COPD患者随机分为治疗组(35例)和对照组(34例)。对照组给予常规治疗,治疗组在常规治疗基础上给予吸入信必可都保(160μg/次,2次/d)治疗8周。观察两组用药前后肺功能改变、呼吸困难评分变化、6 min步行距离(6-MWD)及8周内COPD急性加重的次数。结果:用药8周后治疗组与治疗前比较FEV1、FEV1/FVC上升及呼吸困难评分下降有显著性意义(P<0.01),对照组治疗前后无显著性差异。两组治疗前后6 min步行距离无显著性差异(P>0.05)。8周内COPD急性加重的次数两组比较差异有显著性(P<0.05)。信必可都保的常见不良反应为口咽部不适、声音嘶哑(5例,14%)。结论:信必可都保治疗重度稳定期COPD,能明显改善患者的临床症状及肺功能,减少急性发作,且安全可靠。

作者高立芳姜素文

机构地区天津市第三中心医院

出处《天津药学》 2011年第6期30-32,共3页 Tianjin Pharmacy

关键词信必可都保慢性阻塞性肺疾病呼吸困难评分肺功能 6 min步行距离

分类号 R974 [医药卫生—药品]

引文网络
相关文献

参考文献8

1慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量：8233
2Panwels R A, Buist A S, Calverley P M, et al. Global strategy for the di- agnosis, management, and prevention of chronic obstructive pulmonary disease, NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease( GOLD ) Workshop summary . Am J Respir Crit Care Med, 2001, 163(5): 1256.
3Blats L, Bourbbeau J, Sheehy O, et al. Inhaled corticosteroids inCOPD: deter minants of use and trends in patient persistence with treatment. Can Respir J,2004,11 ( 1 ) :27.
4Eickelberg U, RothM, Lorx R, et al. Ligand - independent activation of the glucocorticoid receptor by beta2 - adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle ceils. J Bio Chen, 1999, 274(2): 1005.
5Canis R, Demirkok S S, Osar Z, et al. Effects of inhaled budesonide on insulin sensitivity in nondiabetic patients with asthma and chronic ob- structive oulmonarv disease . Adv Ther. 2007. 24(3) :560.
6李艳丽,孙芳.信必可都保治疗支气管哮喘50例临床分析[J].疾病监测与控制,2009,3(8):468-469. 被引量：2
7Decram er M, Fergu son G. Clinical safety of long acting beta2 - agonist and inhaled cortisterroid combination therapy in COPD . COPD, 2006, 3 (3) :163.
8何权瀛.六分钟步行测验及其临床应用[J].中华内科杂志,2006,45(11):950-951. 被引量：82

二级参考文献13

1有创-无创序贯机械通气多中心研究协作组.以肺部感染控制窗为切换点行有创与无创序贯机械通气治疗慢性阻塞性肺疾病所致严重呼吸衰竭的随机对照研究[J].中华结核和呼吸杂志,2006,29(1):14-18. 被引量：279
2McGavin CR,Gupta SP,McHardy GJ.Twelve-minute walking test for assessing disability in chronic bronchitis.Br Med J,1976,1:822-823.
3Guyatt GH,Sullivan MJ,Thompson PJ,et al.The 6-minute walk:a new measure of exercise capacity in patients with chronic heart failure.Can Med Assoc J,1985,132:919-923.
4Lipkin DP,Scriven AJ,Crake T,et al.Six minute walking test for assessing exercise capacity in chronic heart failure.Br Med J (Clin Res Ed),1986,292:653-655.
5ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories.ATS statement:guidelines for the six-minute walk test.Am J Respir Crit Care Med,2002,166:111-117.
6Enright PL,Sherrill DL.Reference equations for the six-minute walk in healthy adults.Am J Respir Crit Care Med,1998,158(5 Pt 1):1384-1387.
7GOLD Executive Committee[DB/OL].Guidelines:Global Strategy for Diagnosis,Management,and Prevention of COPD,November 2006[2006-11-18].http://www.goldcopd.com/Guidelineitem.asp? l1 =2-12 = 1&intId =989.
8Celli BR,MacNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946.
9Celli BR,Cote CG,Marin JM,ct al.The body mass index,airflow obstruction,dyspnea and exercise capacity index in chronic obstructive pulmonary disease.N Engl J Med,2004,350:1005-1012.
10冉丕鑫王辰姚婉贞等.我国部分地区慢性阻塞性肺疾病流行病学研究[J].中华结核和呼吸杂志,2007,.